Sunshine Biopharma Current Debt

SBFMW Stock  USD 0.08  0.03  27.45%   
Sunshine Biopharma has over 657,705 in debt which may indicate that it relies heavily on debt financing. At this time, Sunshine Biopharma's Short and Long Term Debt Total is fairly stable compared to the past year. Short and Long Term Debt is likely to climb to about 4.4 M in 2024, whereas Short Term Debt is likely to drop slightly above 112.7 K in 2024. . Sunshine Biopharma's financial risk is the risk to Sunshine Biopharma stockholders that is caused by an increase in debt.

Asset vs Debt

Equity vs Debt

Sunshine Biopharma's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Sunshine Biopharma's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Sunshine Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Sunshine Biopharma's stakeholders.
For most companies, including Sunshine Biopharma, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Sunshine Biopharma Warrant, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Sunshine Biopharma's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Book Value
24.943
Operating Margin
(0.18)
Profit Margin
(0.15)
Return On Assets
(0.09)
Return On Equity
(0.18)
At this time, Sunshine Biopharma's Total Current Liabilities is fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to climb to about 28.7 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 480.3 K in 2024.
  
Check out the analysis of Sunshine Biopharma Fundamentals Over Time.
For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.

Sunshine Biopharma Financial Rating

Sunshine Biopharma Warrant financial ratings play a critical role in determining how much Sunshine Biopharma have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Sunshine Biopharma's borrowing costs.
Piotroski F Score
3
FrailView
Beneish M Score
(1.82)
Possible ManipulatorView

Sunshine Biopharma Debt to Cash Allocation

Many companies such as Sunshine Biopharma, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Sunshine Biopharma Warrant has accumulated 657.71 K in total debt with debt to equity ratio (D/E) of 8.98, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Sunshine Biopharma has a current ratio of 83.39, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Note, when we think about Sunshine Biopharma's use of debt, we should always consider it together with its cash and equity.

Sunshine Biopharma Total Assets Over Time

Sunshine Biopharma Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Sunshine Biopharma uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Sunshine Biopharma Debt Ratio

    
  2.28   
It appears most of the Sunshine Biopharma's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Sunshine Biopharma's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Sunshine Biopharma, which in turn will lower the firm's financial flexibility.

Sunshine Net Debt

Net Debt

(14.85 Million)

Sunshine Biopharma reported Net Debt of (15.63 Million) in 2023

Understaning Sunshine Biopharma Use of Financial Leverage

Sunshine Biopharma financial leverage ratio helps in determining the effect of debt on the overall profitability of the company. It measures Sunshine Biopharma's total debt position, including all of outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Sunshine Biopharma assets, the company is considered highly leveraged. Understanding the composition and structure of overall Sunshine Biopharma debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business and if it is worth investing in it. Financial leverage can amplify the potential profits to Sunshine Biopharma's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Sunshine Biopharma's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets).
Last ReportedProjected for Next Year
Net Debt-15.6 M-14.9 M
Short and Long Term Debt Total657.7 KM
Short Term Debt118.7 K112.7 K
Long Term Debt2.2 M1.2 M
Short and Long Term Debt4.2 M4.4 M
Net Debt To EBITDA 3.37  3.54 
Debt To Equity 0.03  0.03 
Interest Debt Per Share 3.27  3.10 
Debt To Assets 0.02  0.02 
Long Term Debt To Capitalization 0.02  0.03 
Total Debt To Capitalization 0.03  0.03 
Debt Equity Ratio 0.03  0.03 
Debt Ratio 0.02  0.02 
Cash Flow To Debt Ratio(13.34)(12.67)
Please read more on our technical analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Sunshine Stock Analysis

When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.